Medical Oncology
ONC · guidelines, resources & primary literature
Guidelines & Resources
General
- LearnOncology.ca — Oncology Basics — LearnOncology.ca
- Cancer Guidelines by Tumour Site — AHS Cancer Management Guidelines — Alberta Health Services
- NCCN Guidelines by Cancer Type — NCCN Guidelines — NCCN
- ESMO Guidelines — ESMO
- WHO Classification of Tumours — WHO Tumour Classification — PathologyOutlines
- Immunohistochemical Stains — IHC and Special Stains — PathologyOutlines
Pharmacotherapy
- Principles of Systemic Treatment – Drug Classes — Pharmacotherapy Overview — LearnOncology.ca
- Chemotherapy Protocols — BC Cancer Chemotherapy Protocols — BC Cancer
- Cancer Drug Index — BC Cancer
- Febrile Neutropenia — BC Cancer Cancer Management Manual
- SCIMMUNE Protocol — Management of Immunotherapy Toxicities — BC Cancer 2025
- Management of Toxicities from Immunotherapy — ESMO 2022
- Outpatient Cancer Drug Benefit Program — Alberta Health Services 2026
Personal Notes
Colorectal
- Localised Colon Cancer — ESMO
- Early Stage Colon Cancer — Alberta Health Services 2026
- Localised Rectal Cancer — ESMO
- Early-Stage Rectal Cancer — Alberta Health Services 2026
- Colorectal Cancer Surveillance — Alberta Health Services 2019
- Metastatic Colorectal Cancer — ESMO
- Metastatic Colorectal Cancer — Alberta Health Services 2025
Breast
- Staging Investigations — Alberta Health Services 2024
- Early Breast Cancer — ESMO
- Metastatic Breast Cancer — ESMO
- Adjuvant Radiation Therapy for Invasive Breast Cancer — Alberta Health Services 2015
- Follow-Up Care for Early-Stage Breast Cancer — Alberta Health Services 2021
Lung
- Early Stage and Locally Advanced NSCLC — ESMO
- Stage I, II, and Resectable Stage III NSCLC — Alberta Health Services 2025
- Unresectable Stage III NSCLC — Alberta Health Services 2025
- Surveillance for Early-Stage NSCLC — Alberta Health Services 2024
- Non-Oncogene-Addicted Metastatic NSCLC — ESMO
- Advanced NSCLC: Driver Mutation Negative — Alberta Health Services 2024
- Oncogene-Addicted Metastatic NSCLC — ESMO
- Advanced NSCLC: Driver Mutation Positive — Alberta Health Services 2024
- Small Cell Lung Cancer — ESMO
- SCLC and Mesothelioma Summary — Alberta Health Services 2023
Primary Literature
Lung
Screening
- NLST — Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening — NEJM 2011
- NELSON — Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial — NEJM 2020
Immunotherapy
- KEYNOTE-024 — Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer — NEJM 2016
- KEYNOTE-189 — Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer — NEJM 2018
- PACIFIC — Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer — NEJM 2017
- CheckMate 816 — Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer — NEJM 2022
- IMpower133 — First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer — NEJM 2018
Targeted Therapy
- FLAURA — Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer — NEJM 2018
- ADAURA — Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer — NEJM 2020
- ALEX — Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer — NEJM 2017
- LAURA — Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC — NEJM 2024
Colorectal
Chemotherapy
- MOSAIC — Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer — NEJM 2004
- IDEA — Duration of Adjuvant Chemotherapy for Stage III Colon Cancer — NEJM 2018
Immunotherapy
- KEYNOTE-177 — Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer — NEJM 2020
- Cercek et al. — PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer — NEJM 2022
- NICHE-2 — Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer — NEJM 2024
- CheckMate 8HW — Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer — NEJM 2024
Targeted Therapy
- Hurwitz — Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer — NEJM 2004
- CRYSTAL — Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer — NEJM 2009
- BEACON — Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer — NEJM 2019
Radiation Therapy
- PROSPECT — Preoperative Treatment of Locally Advanced Rectal Cancer — NEJM 2023
Breast
Diagnostics/Biomarkers
- TAILORx — Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer — NEJM 2018
- RxPONDER — 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer — NEJM 2021
Endocrine Therapy
- SOFT/TEXT — Adjuvant Ovarian Suppression in Premenopausal Breast Cancer — NEJM 2015
Immunotherapy
- KEYNOTE-522 — Pembrolizumab for Early Triple-Negative Breast Cancer — NEJM 2020
Targeted Therapy
- HERA — Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer — NEJM 2005
- APHINITY — Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer — NEJM 2017
- OlympiA — Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer — NEJM 2021
- PALOMA-2 — Palbociclib and Letrozole in Advanced Breast Cancer — NEJM 2016
- MONALEESA-2 — Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer — NEJM 2016
Antibody-Drug Conjugates
- KATHERINE — Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer — NEJM 2019
- DESTINY-Breast03 — Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer — NEJM 2022
- DESTINY-Breast04 — Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer — NEJM 2022